Save time and get answers to complex questions with AI chat
Dabrafenib and trametinib cost?When oxcarbazepine patent expired?Drugpatentwatch market analysis industry today?What is dabrafenib mesylate msn patent issue?Is clarinex off patent?
See the DrugPatentWatch profile for Tirofiban
Tirofiban is used to prevent and treat blood clots by blocking platelet activation. It’s typically used in acute coronary settings such as non–ST-elevation acute coronary syndrome (NST-ACS/NSTEMI) and during/around percutaneous coronary intervention (PCI) to reduce the risk of heart-attack–related clotting [1].
Clinicians use tirofiban in hospital to lower the chance of worsening ischemia and thrombotic complications in patients where platelet-driven clot formation is a major concern, including when procedures like PCI are planned or underway [1].
Tirofiban is administered intravenously (IV), generally as a continuous infusion in acute care settings [1].
Tirofiban blocks the platelet glycoprotein IIb/IIIa receptor, which helps prevent platelets from sticking together and forming clots [1].
Because it works on platelets to reduce clot formation, tirofiban can increase bleeding risk. Patients are typically monitored for bleeding and other complications during treatment [1].
Other Questions About Tirofiban :